M Reck

Summary

Country: Germany

Publications

  1. ncbi request reprint Randomized phase III trial of paclitaxel, etoposide, and carboplatin versus carboplatin, etoposide, and vincristine in patients with small-cell lung cancer
    Martin Reck
    Department of Thoracic Oncology, Hospital Grosshansdorf, Hamburg, Germany
    J Natl Cancer Inst 95:1118-27. 2003
  2. ncbi request reprint Gefitinib monotherapy in chemotherapy-naive patients with inoperable stage III/IV non-small-cell lung cancer
    Martin Reck
    Department of Thoracic Oncology, Hospital Grobhansdorf, Germany
    Clin Lung Cancer 7:406-11. 2006
  3. ncbi request reprint Single-agent pemetrexed or sequential pemetrexed/gemcitabine as front-line treatment of advanced non-small cell lung cancer in elderly patients or patients ineligible for platinum-based chemotherapy: a multicenter, randomized, phase II trial
    Cesare Gridelli
    Division of Medical Oncology, S G Moscati Hospital, Avellino, Italy
    J Thorac Oncol 2:221-9. 2007
  4. doi request reprint A major step towards individualized therapy of lung cancer with gefitinib: the IPASS trial and beyond
    Martin Reck
    Department of Thoracic Oncology, Hospital Grosshansdorf, Grosshansdorf, Germany
    Expert Rev Anticancer Ther 10:955-65. 2010
  5. doi request reprint Reviewing the safety of erlotinib in non-small cell lung cancer
    Martin Reck
    Department of Thoracic Oncology, Hospital Grosshansdorf, Woehrendamm 80, Grosshansdorf, Germany
    Expert Opin Drug Saf 10:147-57. 2011
  6. ncbi request reprint Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer
    Martin Reck
    Martin Reck, LungenClinic Grosshansdorf, Airway Research Center North, Grosshansdorf Michael Thomas, Translational Lung Research Center Heidelberg, Thoraxklinik im Universitätsklinikum Heidelberg, Heidelberg, Germany Alexander Luft, Leningrad Regional Clinical Hospital, Leningrad, Russia Aleksandra Szczesna, Mazowieckie Centrum Leczenia Chorob Pluc i Gruzlicy w Otwocku, Otwocku, Poland Libor Havel, Hospital Na Bulovce, Prague, Czech Republic Sang We Kim, Asan Medical Center and University of Ulsan College of Medicine, Seoul, Korea Wallace Akerley, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT Maria Catherine Pietanza, Memorial Sloan Kettering Cancer Center, New York, NY Kathryn Gold, University of Texas MD Anderson Cancer Center, Houston, TX Leora Horn, Vanderbilt Ingram Cancer Center David Spigel, Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN Anne Pieters, Teresa Kong Sanchez, and Justin Fairchild, Bristol Myers Squibb, Princeton, France
    J Clin Oncol . 2016
  7. doi request reprint The Effect of Necitumumab in Combination with Gemcitabine plus Cisplatin on Tolerability and on Quality of Life: Results from the Phase 3 SQUIRE Trial
    Martin Reck
    Department of Thoracic Oncology, LungenClinic Grosshansdorf, Airway Research Center North, Grosshansdorf, Germany Electronic address
    J Thorac Oncol 11:808-18. 2016
  8. doi request reprint Anti-angiogenic-specific adverse events in patients with non-small cell lung cancer treated with nintedanib and docetaxel
    Martin Reck
    Department of Thoracic Oncology, Lung Clinic Grosshansdorf, Airway Research Center North ARCN, Member of the German Center for Lung Research DZL, Grosshansdorf, Germany Electronic address
    Lung Cancer 90:267-73. 2015
  9. doi request reprint A randomized, double-blind, placebo-controlled phase 2 study of tigatuzumab (CS-1008) in combination with carboplatin/paclitaxel in patients with chemotherapy-naïve metastatic/unresectable non-small cell lung cancer
    Martin Reck
    LungClinic Grosshansdorf, Member of the German Centre for Lung Research DZL, Grosshansdorf, Germany Electronic address
    Lung Cancer 82:441-8. 2013
  10. doi request reprint Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial
    M Reck
    Department of Thoracic Oncology, Hospital Grosshansdorf, Grosshansdorf, Germany
    Ann Oncol 24:75-83. 2013

Detail Information

Publications75

  1. ncbi request reprint Randomized phase III trial of paclitaxel, etoposide, and carboplatin versus carboplatin, etoposide, and vincristine in patients with small-cell lung cancer
    Martin Reck
    Department of Thoracic Oncology, Hospital Grosshansdorf, Hamburg, Germany
    J Natl Cancer Inst 95:1118-27. 2003
    ....
  2. ncbi request reprint Gefitinib monotherapy in chemotherapy-naive patients with inoperable stage III/IV non-small-cell lung cancer
    Martin Reck
    Department of Thoracic Oncology, Hospital Grobhansdorf, Germany
    Clin Lung Cancer 7:406-11. 2006
    ..However, little is known of its activity as monotherapy in chemotherapy-naive patients. This phase II study (1839IL/0456) evaluated first-line gefitinib in patients with advanced-stage NSCLC...
  3. ncbi request reprint Single-agent pemetrexed or sequential pemetrexed/gemcitabine as front-line treatment of advanced non-small cell lung cancer in elderly patients or patients ineligible for platinum-based chemotherapy: a multicenter, randomized, phase II trial
    Cesare Gridelli
    Division of Medical Oncology, S G Moscati Hospital, Avellino, Italy
    J Thorac Oncol 2:221-9. 2007
    ....
  4. doi request reprint A major step towards individualized therapy of lung cancer with gefitinib: the IPASS trial and beyond
    Martin Reck
    Department of Thoracic Oncology, Hospital Grosshansdorf, Grosshansdorf, Germany
    Expert Rev Anticancer Ther 10:955-65. 2010
    ..Furthermore, the clinical implications and future challenges for gefitinib are highlighted...
  5. doi request reprint Reviewing the safety of erlotinib in non-small cell lung cancer
    Martin Reck
    Department of Thoracic Oncology, Hospital Grosshansdorf, Woehrendamm 80, Grosshansdorf, Germany
    Expert Opin Drug Saf 10:147-57. 2011
    ..It is also an emerging option in other treatment settings in NSCLC...
  6. ncbi request reprint Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer
    Martin Reck
    Martin Reck, LungenClinic Grosshansdorf, Airway Research Center North, Grosshansdorf Michael Thomas, Translational Lung Research Center Heidelberg, Thoraxklinik im Universitätsklinikum Heidelberg, Heidelberg, Germany Alexander Luft, Leningrad Regional Clinical Hospital, Leningrad, Russia Aleksandra Szczesna, Mazowieckie Centrum Leczenia Chorob Pluc i Gruzlicy w Otwocku, Otwocku, Poland Libor Havel, Hospital Na Bulovce, Prague, Czech Republic Sang We Kim, Asan Medical Center and University of Ulsan College of Medicine, Seoul, Korea Wallace Akerley, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT Maria Catherine Pietanza, Memorial Sloan Kettering Cancer Center, New York, NY Kathryn Gold, University of Texas MD Anderson Cancer Center, Houston, TX Leora Horn, Vanderbilt Ingram Cancer Center David Spigel, Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN Anne Pieters, Teresa Kong Sanchez, and Justin Fairchild, Bristol Myers Squibb, Princeton, France
    J Clin Oncol . 2016
    ..This randomized, double-blind phase III study evaluated the efficacy and safety of ipilimumab or placebo plus etoposide and platinum in patients with newly diagnosed extensive-stage disease SCLC...
  7. doi request reprint The Effect of Necitumumab in Combination with Gemcitabine plus Cisplatin on Tolerability and on Quality of Life: Results from the Phase 3 SQUIRE Trial
    Martin Reck
    Department of Thoracic Oncology, LungenClinic Grosshansdorf, Airway Research Center North, Grosshansdorf, Germany Electronic address
    J Thorac Oncol 11:808-18. 2016
    ..Here we characterize health-related quality of life (HRQoL) and tolerability results...
  8. doi request reprint Anti-angiogenic-specific adverse events in patients with non-small cell lung cancer treated with nintedanib and docetaxel
    Martin Reck
    Department of Thoracic Oncology, Lung Clinic Grosshansdorf, Airway Research Center North ARCN, Member of the German Center for Lung Research DZL, Grosshansdorf, Germany Electronic address
    Lung Cancer 90:267-73. 2015
    ..We evaluated the frequency of characteristic adverse events (AEs) commonly seen with existing anti-angiogenic agents...
  9. doi request reprint A randomized, double-blind, placebo-controlled phase 2 study of tigatuzumab (CS-1008) in combination with carboplatin/paclitaxel in patients with chemotherapy-naïve metastatic/unresectable non-small cell lung cancer
    Martin Reck
    LungClinic Grosshansdorf, Member of the German Centre for Lung Research DZL, Grosshansdorf, Germany Electronic address
    Lung Cancer 82:441-8. 2013
    ..The objective of this study was to investigate the antitumor effects of tigatuzumab combined with carboplatin/paclitaxel in chemotherapy-naïve patients with metastatic/unresectable non-small cell lung cancer (NSCLC)...
  10. doi request reprint Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial
    M Reck
    Department of Thoracic Oncology, Hospital Grosshansdorf, Grosshansdorf, Germany
    Ann Oncol 24:75-83. 2013
    ..This phase 2 study evaluated ipilimumab+paclitaxel (Taxol)/carboplatin in extensive-disease-small-cell lung cancer (ED-SCLC)...
  11. doi request reprint Baseline quality of life and performance status as prognostic factors in patients with extensive-stage disease small cell lung cancer treated with pemetrexed plus carboplatin vs. etoposide plus carboplatin
    Martin Reck
    Department of Thoracic Oncology, Hospital Grosshansdorf, Wöhrendamm, Grosshansdorf, Germany
    Lung Cancer 78:276-81. 2012
    ....
  12. doi request reprint What future opportunities may immuno-oncology provide for improving the treatment of patients with lung cancer?
    M Reck
    Department of Thoracic Oncology, Hospital Grosshansdorf, Grosshansdorf, Germany
    Ann Oncol 23:viii28-34. 2012
    ..e. in the adjuvant or metastatic settings). In addition, it will be important to determine if immunotherapies are most effective when used alone or in combination with other agents...
  13. pmc Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of experts
    M Reck
    Department of Thoracic Oncology, Hospital Grosshansdorf, Grosshansdorf, Germany
    Ann Oncol 23:1111-20. 2012
    ..Severe pulmonary haemorrhage (PH) is a rare but serious potential adverse event associated with bevacizumab therapy for advanced non-squamous non-small-cell lung cancer (NSCLC)...
  14. doi request reprint [Chemotherapy of malignant pleural mesothelioma: have we made any progress?]
    M Reck
    Onkologischer Schwerpunkt, Krankenhaus Grosshansdorf
    Zentralbl Chir 133:238-42. 2008
    ....
  15. doi request reprint Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study
    Martin Reck
    Department of Thoracic Oncology, Hospital Grosshansdorf, Grosshansdorf, Germany
    J Thorac Oncol 5:1616-22. 2010
    ..Here, we report safety and efficacy data from a large, global, open-label, phase IV trial of erlotinib (Tarceva Lung Cancer Survival Treatment)...
  16. doi request reprint Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil
    Martin Reck
    Department of Thoracic Oncology, Hospital Grosshansdorf, Wohrendamm 80, 22927 Grosshansdorf, Germany
    J Clin Oncol 27:1227-34. 2009
    ..This randomized phase III trial investigated the efficacy and safety of cisplatin/gemcitabine (CG) plus bevacizumab in this setting...
  17. doi request reprint Gefitinib in the treatment of advanced non-small-cell lung cancer
    Martin Reck
    Department of Thoracic Oncology, Hospital Grosshansdorf, Grosshansdorf, Germany
    Expert Rev Anticancer Ther 9:401-12. 2009
    ..As a result, gefitinib is expected to have a large impact in the management of pretreated patients with NSCLC...
  18. doi request reprint Pemetrexed in the treatment of malignant mesothelioma: results from an expanded access program in Germany
    Martin Reck
    Department of Pneumology and Thoracic Surgery, Hospital Grosshansdorf, Woehrendamm 80, D 22927 Grosshansdorf, Germany
    Respir Med 104:142-8. 2010
    ..Treatment of pleural MM with pemetrexed alone or in combination with platinum was safe and active as first and second-line therapy...
  19. doi request reprint Examining the safety profile of angiogenesis inhibitors: implications for clinical practice
    Martin Reck
    Department of Thoracic Oncology, Hospital Grosshansdorf, Grosshansdorf, Germany
    Target Oncol 5:257-67. 2010
    ..Using literature from peer-reviewed journals, this review considers different antiangiogenic agents and their safety profiles, focusing on the potential impact of these data on the treatment of patients with NSCLC...
  20. doi request reprint Management of the cutaneous side effects of therapeutic epidermal growth factor receptor inhibition
    Martin Reck
    Onkologischer Schwerpunkt, Krankenhaus Grosshansdorf, Germany
    Onkologie 33:470-9. 2010
    ..Active rash management can effectively resolve rash to ensure that patient compliance is maintained, without necessitating dose interruptions or treatment withdrawal...
  21. doi request reprint [Treatment of small-cell lung cancer]
    M Reck
    Krankenhaus Grosshansdorf, Zentrum fur Pneumologie und Thoraxchirurgie, Grosshansdorf, Deutschland
    Internist (Berl) 52:130, 132-4, 136-7. 2011
    ..Up to now neither molecular targeted therapies nor cytotoxic or immunological maintenance strategies have provided any benefit to patients with SCLC...
  22. doi request reprint BIBF 1120 for the treatment of non-small cell lung cancer
    Martin Reck
    Hospital Grosshansdorf, Department of Thoracic Oncology, Grosshansdorf, Germany
    Expert Opin Investig Drugs 19:789-94. 2010
    ..Angiogenesis, the formation of new blood vessels from the pre-existing vasculature, is a fundamental process for tumor growth and development. Tumor vasculature is therefore emerging as an important target for cancer therapy...
  23. doi request reprint Sunitinib in combination with gemcitabine plus cisplatin for advanced non-small cell lung cancer: a phase I dose-escalation study
    Martin Reck
    Department of Thoracic Oncology, Hospital Grosshansdorf, Grosshansdorf 22927, Germany
    Lung Cancer 70:180-7. 2010
    ..To determine the maximum tolerated dose (MTD) of sunitinib plus gemcitabine/cisplatin for first-line treatment of patients with advanced non-small cell lung cancer (NSCLC). Safety, pharmacokinetics, and antitumor activities were evaluated...
  24. pmc Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
    M Reck
    Department of Thoracic Oncology, Krankenhaus Grosshansdorf, Grosshansdorf
    Ann Oncol 21:1804-9. 2010
    ..We report the final overall survival (OS) analysis from the phase III AVAiL trial...
  25. doi request reprint Tissue sampling in lung cancer: a review in light of the MERIT experience
    Martin Reck
    Grosshansdorf Hospital, Grosshansdorf, Wohrendamm 80, 22927 Grosshansdorf, Germany
    Lung Cancer 74:1-6. 2011
    ..Applying the lessons learned from tissue sampling and molecular testing in MERIT and other major NSCLC trials will be essential in paving the way for the routine use of biomarker analyses in clinical practice...
  26. doi request reprint A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer
    M Reck
    Department of Thoracic Oncology, Hospital Grosshansdorf, Grosshansdorf, Hamburg, Germany
    Ann Oncol 22:1374-81. 2011
    ..To assess the efficacy, safety, tolerability and pharmacokinetics of BIBF 1120 in patients with stage IIIB/IV non-small-cell lung cancer (NSCLC)...
  27. doi request reprint Advances in anti-VEGF and anti-EGFR therapy for advanced non-small cell lung cancer
    Martin Reck
    Department of Thoracic Oncology, Hospital Grosshansdorf, Wohrendamm 80, 22927 Grosshansdorf, Germany
    Lung Cancer 63:1-9. 2009
    ..We will review the clinical data for various novel therapies and identify how these agents are improving outcomes in the first- and second-line treatment of advanced NSCLC...
  28. ncbi request reprint EGFR tyrosine kinase inhibitors in non-small cell lung cancer: report of a 3-year compassionate use experience with gefitinib in stage IIIB/IV outpatients
    Martin Reck
    Krankenhaus Grosshansdorf, Zentrum für Thoraxchirurgie, Grosshansdorf, Germany
    Onkologie 28:623-7. 2005
    ..Since March 2002, 240 patients with advanced stage IIIB/IV non-small cell lung cancer (NSCLC) have been treated inside a compassionate use program with oral gefitinib (250 mg o.d.)...
  29. ncbi request reprint Pemetrexed-cisplatin combination in mesothelioma
    Martin Reck
    Department of Thoracic Oncology, Hospital Grosshansdorf, Wohrendamm 80, 22927 Grosshansdorf, Germany
    Expert Rev Anticancer Ther 5:231-7. 2005
    ..This review reflects the development of chemotherapy in malignant pleural mesothelioma, discusses the results of the EMPHACIS trial, and outlines further developments for pemetrexed-containing regimens in malignant pleural mesothelioma...
  30. ncbi request reprint Topotecan and etoposide as first-line therapy for extensive disease small cell lung cancer: a phase II trial of a platinum-free regimen
    Martin Reck
    Department of Thoracic Oncology, Hospital Grosshansdorf, Wohrendamm 80, 22927 Grosshansdorf, Germany
    Lung Cancer 48:409-13. 2005
    ..The regimen showed a tolerable safety profile. Since drug scheduling plays a critical role in the combination of topoisomerase I and II inhibitors, concurrent administration of topotecan and etoposide might increase the efficacy...
  31. ncbi request reprint Chemotherapy in stage-IV NSCLC
    Martin Reck
    Department of Thoracic Oncology, Hospital Grosshansdorf, Center of Pneumology and Thoracic Surgery, Woehrendamm 80, D 22927 Grosshansdorf, Germany
    Lung Cancer 45:S217-22. 2004
    ..The novel antifolate Pemetrexed proved comparable activity to docetaxel with significantly reduced toxicities...
  32. ncbi request reprint [EGFR/HER1 inhibition: an example of new targeted therapies in non-small cell lung cancer]
    Martin Reck
    Onkologischer Schwerpunkt, Krankenhaus Grosshansdorf, Grosshansdorf
    Med Klin (Munich) 100:785-93. 2005
    ..New less Adenotoxic drugs are urgently needed. One of the targets of new agents is the human epidermal growth factor receptor (EGFR/HER1), and agents targeting this receptor include erlotinib, gefitinib and cetuximab...
  33. ncbi request reprint Beyond the TRIBUTE trial: integrating HER1/EGFR tyrosine kinase inhibitors with chemotherapy in advanced NSCLC
    Martin Reck
    Department of Thoracic Oncology, Hospital Grosshansdorf, Woehrendamn 80, 22927 Grosshansdorf, Germany
    Future Oncol 2:47-51. 2006
    ..Ongoing studies investigating alternative schedules and sequences of administration with chemotherapy will help clinicians to determine how agents such as erlotinib can best be combined with standard cytotoxic agents...
  34. ncbi request reprint Efficient palliation in patients with small-cell lung cancer by a combination of paclitaxel, etoposide and carboplatin: quality of life and 6-years'-follow-up results from a randomised phase III trial
    Martin Reck
    Department of Thoracic Oncology, Hospital Grosshansdorf, Wohrendamm 80, D 22927 Grosshansdorf, Germany
    Lung Cancer 53:67-75. 2006
    ....
  35. ncbi request reprint Current approaches in chemotherapy of advanced and metastatic non-small cell lung cancer (NSCLC)
    Martin Reck
    Department of Thoracic Oncology, Hospital Grosshansdorf, Center of Pneumology and Thoracic Surgery, Grosshansdorf, Germany
    Anticancer Res 25:1501-6. 2005
    ..Among the new oral tyrosine kinase inhibitors, Erlotinib proved to be active in second- and third-line treatments, whereas in first-line treatment, no survival benefit has been observed to date...
  36. ncbi request reprint Treating non-small-cell lung cancer first line with erlotinib monotherapy in elderly patients: discussion of a case series
    Martin Reck
    Department of Thoracic Oncology, Hospital Grosshansdorf, Germany
    Onkologie 30:515-8. 2007
    ..Non-small-cell lung cancer (NSCLC) predominantly occurs in the elderly, a group that has been historically undertreated for various reasons such as perceived frailty and comorbidity...
  37. ncbi request reprint [Phase II-trial of tirapazamine in combination with cisplatin and gemcitabine in patients with advanced non-small-cell-lung-cancer (NSCLC)]
    M Reck
    Onkologischer Schwerpunkt, Krankenhaus Grosshansdorf, Grosshansdorf
    Pneumologie 58:845-9. 2004
    ..Treatment of advanced and metastatic NSCLC with TPZ in combination with Gemcitabine/Cisplatin was well feasible and showed results recording to currently published data. The results of a following phase III-trial are awaited...
  38. ncbi request reprint PARAMOUNT: Phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo plus BSC immediately following induction treatment with pem plus cisplatin for advanced nonsquamous non-small cell lung cancer (NSCLC)
    L G Paz-Ares
    Hospital Universitario Virgen del Rocio, Seville, Spain San Camillo Forlanini Hospital, Rome, Italy Medical Oncology Department, Institute of Oncology, Bucharest, Romania Thoraxklinik at the University of Heidelberg, Heidelberg, Germany Montpellier University Hospital, Montpellier, France Az Ospedale S Gerardo, Monza, Italy Le Mans Regional Hospital, Le Mans, France Jawaharlal Nehru Cancer Hospital and Research Centre, Bhopal, India Ambulantes Krebszentrum Hamburg, Hamburg, Germany Hospital Großhansdorf, Großhansdorf, Germany Eli Lilly and Co, Indianapolis, IN Lilly France, Paris, France Lilly Oncology Europe, Houten, Netherlands SG Moscati Hospital, Avellino, Italy
    J Clin Oncol 29:CRA7510. 2011
    ..CRA7510 Background: The PARAMOUNT trial investigated whether pem continuation maintenance therapy improves progression-free survival (PFS) after pem-cisplatin induction therapy in patients (pts) with advanced nonsquamous NSCLC...
  39. ncbi request reprint Final safety results of BO17704 (AVAiL): A phase III randomized study of first-line bevacizumab (Bv) and cisplatin/gemcitabine (CG) in patients (pts) with advanced or recurrent nonsquamous non-small cell lung cancer (NSCLC)
    V Hirsh
    McGill University Health Centre, Westmount, QC, Canada Regional Centre of Lung Diseases, Poznan, Poland Asklepios Klinikum Gauting, Gauting, Germany Charles University, Praha, Czech Republic Cancer Research Center, Moscow, Russian Federation Princess Margaret Hospital, Toronto, ON, Canada St Vincentius Kliniken, Karlsruhe, Germany F Hoffmann La Roche, Basel, Switzerland Hospital Grosshansdorf, Grosshansdorf, Germany
    J Clin Oncol 27:8039. 2009
    ..This report summarizes overall safety findings from AVAiL...
  40. ncbi request reprint Benefit in lung function improvement and side-effect profile of long-term responders: an analysis of 14 NSCLC patients treated for at least 9 months with gefitinib
    Martin Reck
    Onkologischer Schwerpunkt, Krankenhaus Grosshansdorf, Zentrum für Thoraxchirurgie, Studienkoordination, Wohrendamm 80, D 22927 Grosshansdorf, Germany
    Lung Cancer 50:107-14. 2005
    ....
  41. doi request reprint Phase II study of oral vinorelbine in combination with carboplatin followed by consolidation therapy with oral vinorelbine as single-agent in unresectable localized or metastatic non-small cell lung carcinoma
    Martin Reck
    Krankenhaus Grosshansdorf, Thoracic Oncology, D 22927 Grosshansdorf, Germany
    Lung Cancer 64:319-25. 2009
    ....
  42. ncbi request reprint Efficacy and safety of first-line bevacizumab (Bv) and cisplatin/gemcitabine (CG) in elderly patients (pts) with advanced non-small cell lung cancer (NSCLC) in the BO17704 study (AVAiL)
    N B Leighl
    Princess Margaret Hospital, Toronto, ON, Canada Charles University, Praha, Czech Republic St Vincentius Kliniken Karlsruhe, Karlsruhe, Germany Regional Centre of Lung Diseases, Poznan, Poland F Hoffmann La Roche, Basel, Switzerland Hospital Grosshansdorf, Grosshansdorf, Germany
    J Clin Oncol 27:8050. 2009
    ..A retrospective analysis was performed to assess the efficacy and safety of Bv plus CG in the subpopulation of elderly pts (≥65 years [yrs])...
  43. ncbi request reprint Retrospective study of clinical and radiographic risk factors associated with early onset, severe pulmonary hemorrhage in bevacizumab-treated patients with advanced non-small cell lung cancer (NSCLC)
    A B Sandler
    Vanderbilt University Medical Center, Nashville, TN Royal Victoria Hospital, Montreal, QC, Canada University of Gatzemeier, Hamburg, Germany Hoffman La Roche, Basel, Switzerland Genentech, Inc, South San Francisco, CA University of Vanderbilt, Nashville, TN
    J Clin Oncol 26:8074. 2008
    ..We provide updated results from those analyses pooling additional data from study AVAiL...
  44. doi request reprint [Non-small-cell carcinoma of the lung with invasive Aspergillus infection after chemotherapy]
    A Hermes
    Onkologischer Schwerpunkt, Krankenhaus Grosshansdorf, Germany
    Dtsch Med Wochenschr 136:582-5. 2011
    ..She was cachectic and in a reduced general condition (Karnofsky index 80), but had recently only occasionally used the PEG catheter. There were no inflammatory changes of the skin at the site of the PEG...
  45. ncbi request reprint Long-term survival in SCLC after treatment with paclitaxel, carboplatin and etoposide--a phase II study
    Martin Reck
    Department of Thoracic Oncology, Hospital Grosshansdorf, Woehrendamm 80, D 22927 Grosshansdrof, Hamburg, Germany
    Lung Cancer 39:63-9. 2003
    ..We evaluated the toxicity and feasibility of adding paclitaxel to a standard platinum/etoposide regimen in the first-line treatment of patients with small cell lung cancer (SCLC)...
  46. ncbi request reprint Gefitinib ("Iressa"): a new therapy for advanced non-small-cell lung cancer
    Martin Reck
    Department of Thoracic Oncology, Hospital Grosshansdorf, Woehrendamm 80, Grosshansdorf 22927, Germany
    Respir Med 99:298-307. 2005
    ..Now approved for the treatment of advanced NSCLC in over 25 countries, including Japan and the USA, gefitinib has demonstrated significant clinical benefit in a disease area with limited treatment options...
  47. ncbi request reprint Randomized phase II trial of two dosing schedules of BI 2536, a novel Plk-1 inhibitor, in patients with relapsed advanced or metastatic non-small-cell lung cancer (NSCLC)
    J Von Pawel
    Asklepios Fachkliniken, München Gauting, Germany Hospital Grosshansdorf, Grosshansdorf, Germany University of Freiburg, Freiburg, Germany St Hildegardis Hospital, Mainz, Germany University of Heidelberg, Heidelberg, Germany HSK, Department of Medicine III, Wiesbaden, Germany Johannes Gutenberg University, Mainz, Germany Boehringer Ingelheim Pharma GmbH and Co KG, Biberach, Germany
    J Clin Oncol 26:8030. 2008
    ..We investigated the efficacy, safety and pharmacokinetics (PK) of two dosing schedules of BI 2536 in patients with relapsed advanced or metastatic NSCLC...
  48. ncbi request reprint A population pharmacokinetic analysis for BIBF 1120, an angiokinase inhibitor, in patients with advanced non-small-cell lung cancer (NSCLC)
    M Freiwald
    Boehringer Ingelheim Pharma GmbH and Co KG, Biberach, Germany Pharsight Corporation, Mountain View, CA Boehringer Ingelheim Pharma GmbH and Co KG, Biberach, Germany Asklepios Krankenhaus Hamburg Harburg, Hamburg, Germany Krakenhaus Grosshansdorf Hamburg, Grosshansdorf, Germany Asklepios Kliniken München Gauting, Gauting, Germany
    J Clin Oncol 26:14528. 2008
    ....
  49. ncbi request reprint Randomized, multicenter, open-label phase II study of gemcitabine plus single-dose versus split-dose carboplatin in the treatment of patients with advanced-stage non-small-cell lung cancer
    Wolfgang Schuette
    City Hospital Martha Maria Halle Doelau, 2nd Medical Department, Roentgenstrasse 1, D 06120 Halle, Germany
    Clin Lung Cancer 8:135-9. 2006
    ..Gemcitabine/carboplatin is a convenient and effective treatment for advanced-stage non-small-cell lung cancer (NSCLC), but modification of the schedule to diminish thrombocytopenia is worthwhile...
  50. doi request reprint Targeted therapies for non-small cell lung cancer
    Wolfram C M Dempke
    University of Munich, University Hospital of Grosshadern, D 81377 Munich, Germany
    Lung Cancer 67:257-74. 2010
    ....
  51. ncbi request reprint Randomized, multicenter phase III study of ranpirnase plus doxorubicin (DOX) versus DOX in patients with unresectable malignant mesothelioma (MM)
    M Reck
    Hospital Grosshansdorf, Grosshansdorf, Germany Institute of Oncology, Warsaw, Poland Medical University, Gdansk, Poland Asklepios Klinikum Harburg, Hamburg, Germany Medical University, Zabrze, Poland Lone Star Oncology Consultants, Austin, TX Alfacell, Somerset, NY Asklepios Klinikum Gauting, Gauting, Germany
    J Clin Oncol 27:7507. 2009
    ..3 ms (one year survival: 42%) in a multicentre phase II trial in chemonaive and pretreated pts whom met the Cancer and Leukemia Group B (CALGB) prognostic criteria for group 1-4 (Mikulski, J Clin Oncol 20, 2001)...
  52. ncbi request reprint Randomized phase III trial of amrubicin versus topotecan (Topo) as second-line treatment for small cell lung cancer (SCLC)
    R Jotte
    US Oncology, Denver, CO Asklepios Klinikum Gauting, Munich, Germany Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN University of North Carolina at Chapel Hill, Chapel Hill, NC The Royal Marsden Hospital, Sutton, United Kingdom Piedmont Hematology Oncology Associates, Winston Salem, NC St Vincentius Kliniken, Karlsruhe, Germany Thorax Klinik, Heidelberg, Germany Department of Respiratory Medicine, CHU Sart Tilman, Liege, Belgium Florida Oncology Associates, Orange Park, FL Gasthuisberg University Hospital, Leuven, Belgium Hospital Universitario Virgen de la Victoria, Malaga, Spain Southern Medical Day Care Centre, Wollongong, Australia Hospital Martha Maria Halle Doelau, Halle, Germany The Christie Hospital, Manchester, United Kingdom Hospital Großhansdorf, Großhansdorf, Germany Fundación Jiménez Díaz, Universidad Autonoma, Madrid, Spain Princess Margaret Hospital, Toronto, ON, Canada Celgene Corporation
    J Clin Oncol 29:7000. 2011
    ..The ACT-1 trial compared the safety and efficacy of AMR vs Topo for the 2nd-line treatment of SCLC...
  53. ncbi request reprint A randomized phase II trial of mapatumumab, a TRAIL-R1 agonist monoclonal antibody, in combination with carboplatin and paclitaxel in patients with advanced NSCLC
    J Von Pawel
    Asklepios Klinikum Gauting, Munich, Germany Birmingham Hematology and Oncology Associates, Birmingham, AL Sarah Cannon Research Institute Tennessee Oncology, Nashville, TN Institute of Oncology Bucharest, Bucharest, Romania Hospital Grosshansdorf, Grosshansdorf, Germany Oncology Institute I Chiricuta, Cluj, Romania Human Genome Sciences, Rockville, MD University of Colorado Denver, Aurora, CO
    J Clin Oncol 28:LBA7501. 2010
    ..We conducted this randomized, controlled phase II trial to evaluate mapatumumab in combination with carboplatin and paclitaxel as first-line therapy in advanced non-small call lung cancer (NSCLC)...
  54. ncbi request reprint Phase I study of lapatinib, a dual-tyrosine kinase inhibitor, and pemetrexed in the second-line treatment of advanced or metastatic non-small cell lung cancer
    R Ramlau
    Regional Lung Diseases Hospital, Poznan, Poland University Hospital Heidelberg, Heidelberg, Germany Northern Institute for Cancer Research, Newcastle, United Kingdom Krankenhaus Grosshansdorf, Grosshansdorf, Germany GlaxoSmithKline Oncology, Uxbridge, United Kingdom University of Turin, Turin, Italy
    J Clin Oncol 27:e19027. 2009
    ..The rationale for EGFR/HER2 inhibition in combination with pemetrexed is to demonstrate clinical synergy as previously shown with gemcitabine, another fluoropyrimidine pathway inhibitor...
  55. ncbi request reprint [Non-small cell lung cancer - diagnostics and stage-adapted therapy]
    David F Heigener
    Onkologischer Schwerpunkt, Krankenhaus Grosshansdorf
    Med Klin (Munich) 102:981-8; quiz 989-90. 2007
    ..Stage IV disease is treated with palliative chemotherapy. Newer, so-called targeted therapies are more and more implemented into therapy. There are three substances approved for second-line therapy with response rates of just under 10%...
  56. doi request reprint [A reduced TKI dosage is not associated with loss of activity in EGFR mutated NSCLC patients]
    N Reinmuth
    LungenClinic Grosshansdorf, Onkologischer Schwerpunkt
    Pneumologie 68:619-23. 2014
    ..Patients treated with anti-EGFR tyrosine kinase inhibitors (TKI) may receive dose reduction due to toxicity; however, the impact on treatment efficacy and patient outcome remains unknown...
  57. ncbi request reprint Messenger RNA vaccination in NSCLC: Findings from a phase I/IIa clinical trial
    M Sebastian
    Department of Hematology, Oncology, and Pneumology, University Medical Center, Mainz, Germany Department of Oncology, University Hospital Zurich, Zurich, Switzerland University Hospital Basel, Basel, Switzerland University Hospital, Medical Center II, Tuebingen, Germany Department of Pneumology and Thoracic Surgery, Großhansdorf, Germany University Medical Center Hamburg Eppendorf, Hamburg, Germany Thoraxklinik at the University of Heidelberg, Heidelberg, Germany Policlinic of the Klinikum rechts der Isar, Technical University Munich, Muenchen, Germany Universitätsklinikum Carl Gustav Carus, Dresden, Germany University Hospital Aachen, Aachen, Germany Klinikum Darmstadt, Darmstadt, Germany Internal Medicine V, Pneumology, University Hospital of the Saarland, Homburg Saar, Germany Universitätsklinikum des Saarlandes, Homburg Saar, Germany Universitätsklinikum Tübingen, Tubingen, Germany CureVac GmbH, Tubingen, Germany
    J Clin Oncol 29:2584. 2011
    ..Primary endpoint was assessment of safety and tolerability of CV9201 and secondary endpoints were evaluation of induction of immune response and assessment of anti-tumor activity...
  58. doi request reprint [Treatment of non-small cell lung cancer]
    N Reinmuth
    Internistische Onkologie der Thoraxtumoren, Thoraxklinik am Universitatsklinikum Heidelberg, Amalienstrasse 5, Heidelberg, Germany
    Internist (Berl) 52:1414-21. 2011
    ..This review will summarize the current state of the art in the treatment of non-small cell lung cancer...
  59. ncbi request reprint Bevacizumab (Bv) single-agent maintenance following Bv-based chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): Results from an exploratory analysis of the AVAiL study
    J Mezger
    St Vincentius Kliniken, Karlsruhe, Germany Asklepios Fachkliniken München, Munich, Germany Hospital Grosshansdorf, Grosshansdorf, Germany
    J Clin Oncol 27:e19001. 2009
    ..Given that little data on the use of single-agent Bv as maintenance therapy are currently available, we report here the results of an analysis focused on the maintenance phase of the AVAiL study...
  60. ncbi request reprint PARAMOUNT: Phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo plus BSC immediately following induction treatment with pem plus cisplatin for advanced nonsquamous non-small cell lung cancer (NSCLC)
    L G Paz-Ares
    Hospital Universitario Virgen del Rocio, Seville, Spain San Camillo Forlanini Hospital, Rome, Italy Medical Oncology Department, Institute of Oncology, Bucharest, Romania Thoraxklinik at the University of Heidelberg, Heidelberg, Germany Montpellier University Hospital, Montpellier, France Az Ospedale S Gerardo, Monza, Italy Le Mans Regional Hospital, Le Mans, France Jawaharlal Nehru Cancer Hospital and Research Centre, Bhopal, India Ambulantes Krebszentrum Hamburg, Hamburg, Germany Hospital Großhansdorf, Großhansdorf, Germany Eli Lilly and Co, Indianapolis, IN Lilly France, Paris, France Lilly Oncology Europe, Houten, Netherlands SG Moscati Hospital, Avellino, Italy
    J Clin Oncol 29:CRA7510. 2011
    ....
  61. ncbi request reprint MO19390 (SAiL): Incidence of thromboembolic events and congestive heart failure with first-line bevacizumab (Bv)-based therapy in advanced non-small cell lung cancer (NSCLC)
    N Pavlakis
    Royal North Shore Hospital, Sydney, Australia McGill University, Montreal, QC, Canada Hospital Grosshansdorf, Grosshansdorf, Germany Guangdong General Hospital, Guangzhou, China Centre Oscar Lambret, Lille, France
    J Clin Oncol 27:e19003. 2009
    ..e19003 Background: MO19390 (SAiL) is a single-arm, multicenter, international trial evaluating the safety and efficacy of first-line Bv with standard chemotherapy in over 2,000 patients (pts)...
  62. ncbi request reprint Randomized, double-blind, phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor receptor-1 (IGF-1R), for advanced-stage non-small cell lung cancer (NSCLC)
    S S Ramalingam
    Winship Cancer Institute of Emory University, Atlanta, GA Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN Thorax Klinik, Heidelberg, Germany Massachusetts General Hospital Cancer Center, Boston, MA Central Clinic Bad Berka, Bad Berka, Germany University of Turin, Orbassano, Italy Innere Klinik und Poliklinik Tumorforschung, Essen, Germany University of Perugia, Perugia, Italy Dana Farber Cancer Institute, Boston, MA Shanghai Roche Pharmaceuticals, Shangai, China Hoffmann La Roche, Nutley, NJ Department of Pneumology and Thoracic Surgery, Großhansdorf, Germany
    J Clin Oncol 29:7527. 2011
    ..Based on strong pre-clinical evidence supporting co-inhibition of IGF-1R and epidermal growth factor receptors, we conducted a randomized study of R1507 with erlotinib (E)...
  63. ncbi request reprint Risk of symptomatic central nervous system (CNS) progression and secondary hemorrhage in patients with non-squamous non-small cell lung cancer (NSCLC) receiving bevacizumab (BV)-based first-line therapy
    V Archer
    Roche Products, Ltd, Welwyn Garden City, United Kingdom Krankenhaus Grosshansdorf, Grosshansdorf, Germany University of Vanderbilt, Nashville, TN University of Vanderbilt, Nashville, TN Genentech, Inc, San Francisco, CA Centre René Gauducheau, Nantes Saint Herblain, France
    J Clin Oncol 26:8114. 2008
    ..This preliminary safety report investigates the occurrence of NSCLC progression and CNS hemorrhage among patients receiving Bv...
  64. ncbi request reprint Erlotinib as 1st-line therapy for elderly patients (pts) with advanced non-small cell lung cancer (NSCLC)
    O Merimsky
    Tel Aviv Sourasky Medical Center, Tel Aviv, Israel Princess Margaret Hospital, Lai Chi Kok, Hong Kong Hospital Grosshandorf, Grosshansdorf, Germany Queen Elizabeth Hospital, Kowloon, Hong Kong Asklepios Fachkliniken, Gauting, Germany
    J Clin Oncol 26:19016. 2008
    ..However, experience with 1st-line erlotinib in chemo-naïve elderly pts is currently limited...
  65. doi request reprint Randomized, double-blind phase II study to compare nitroglycerin plus oral vinorelbine plus cisplatin with oral vinorelbine plus cisplatin alone in patients with stage IIIB/IV non-small cell lung cancer (NSCLC)
    N Reinmuth
    LungenClinic Grosshansdorf, Department of Thoracic Oncology, Member of the German Center for Lung Research, Grosshansdorf, Germany
    Lung Cancer 83:363-8. 2014
    ..The main objective of our study was to evaluate the effect of adding nitroglycerin to vinorelbine and cisplatin in a Caucasian population...
  66. ncbi request reprint [Targeted therapy and precision medicine : More than just words in the treatment of lung cancer]
    D F Heigener
    Onkologischer Schwerpunkt, LungenClinic Grosshansdorf, Wohrendamm 80, 22927, Großhansdorf, Deutschland
    Internist (Berl) 57:1243-1249. 2016
    ..For the former two alterations, many inhibitors are already available, whereas for ROS1 and other driving mutations the evidence is sparse due to the rare occurrence of these mutations in NSCLC...
  67. doi request reprint Open, randomized, multi-center phase II study comparing efficacy and tolerability of Erlotinib vs. Carboplatin/Vinorelbin in elderly patients (>70 years of age) with untreated non-small cell lung cancer
    D F Heigener
    Department of Thoracic Oncology, Lung Clinic Grosshansdorf, Member of the German Center for Lung Research DZL, Grosshansdorf, Germany Electronic address
    Lung Cancer 84:62-6. 2014
    ..This study was undertaken to determine whether Erlotinib is non-inferior compared to chemotherapy as a first-line therapy in unselected elderly patients...
  68. ncbi request reprint Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21
    Andrea Bezjak
    Princess Margaret Hospital University Health Network, University of Toronto, Toronto, Ontario, Canada
    J Clin Oncol 24:3831-7. 2006
    ..This report describes the quality of life (QOL) findings of a randomized placebo controlled study of erlotinib, an epidermal growth factor receptor inhibitor, in patients with non-small-cell lung cancer (NSCLC)...
  69. ncbi request reprint A randomized phase II pharmacokinetic and pharmacodynamic study of indisulam as second-line therapy in patients with advanced non-small cell lung cancer
    Denis C Talbot
    Cancer Research UK Medical Oncology Unit, Churchill Hospital, Oxford, UK
    Clin Cancer Res 13:1816-22. 2007
    ..The secondary aims were to determine progression-free survival, to assess the safety and tolerability of indisulam, and to study its pharmacokinetic and pharmacodynamic profile...
  70. doi request reprint Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study
    Lucio Crino
    Department of Medical Oncology, Perugia Hospital, S Andrea delle Fratte, 06156 Perugia, Italy
    J Clin Oncol 26:4253-60. 2008
    ..This phase II, open-label, parallel-group study compared gefitinib with vinorelbine in chemotherapy-naïve elderly patients with advanced non-small-cell lung cancer (NSCLC)...
  71. ncbi request reprint A phase I study of ZD0473 combined with paclitaxel for the treatment of solid malignancies
    Chris Twelves
    Cancer Research UK Department of Medical Oncology, Beatson Laboratories, University of Glasgow, Garscube Estate, Switchback Road, Glasgow, G61 1BD, UK
    Cancer Chemother Pharmacol 52:277-81. 2003
    ..The aim of this open-label phase I study was to determine the maximum tolerated dose (MTD), safety, and antitumour activity of ZD0473 followed by paclitaxel in patients with refractory solid malignancies...
  72. doi request reprint A phase II pharmacodynamic study of erlotinib in patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy
    Enriqueta Felip
    Medical Oncology Service and Pathology Service, Vall d Hebron University Hospital, Barcelona, Spain
    Clin Cancer Res 14:3867-74. 2008
    ..To examine potential markers of clinical benefit and the effects of erlotinib on the epidermal growth factor receptor (EGFR) signaling pathway in advanced non-small cell lung cancer patients refractory to platinum-based chemotherapy...
  73. ncbi request reprint [Therapy for non-small-cell lung carcinoma (NSCLC) in stage IV]
    Karl Matthias Deppermann
    Klinik fur Pneumologie, Ruppiner Klinikum GmbH, Neuruppin, Deutschland
    Onkologie 29:15-9. 2006
  74. doi request reprint Lung Cancer Symptom Scale outcomes in relation to standard efficacy measures: an analysis of the phase III study of pemetrexed versus docetaxel in advanced non-small cell lung cancer
    Filippo De Marinis
    Forlanini Hospital, Rome, Italy
    J Thorac Oncol 3:30-6. 2008
    ..The low response rates and minimal survival gains observed in second-line studies underscore the need to assess treatment efficacy with symptomatic end points...
  75. doi request reprint [Therapy in elderly patients]
    Hendrik C Dienemann
    Thoraxklinik am Universitatsklinikum Heidelberg, Deutschland
    Onkologie 31:15-22. 2008
    ..Retrospective sub-group analyses and studies especially performed in elderly patients, however, show that elderly patients with thoracic tumours, too, may benefit from surgery, radiotherapy, chemotherapy, and targeted therapy...